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Objective: The aim was to investigate whether vitamin D supplementation, combined with a hypocaloric
diet, could have an independent effect on insulin sensitivity in subjects with both overweight and
hypovitaminosis D. Changes from baseline in anthropometric parameters, body composition, glucose tol-
erance, and insulin secretion were considered as secondary outcomes.
Methods: Eighteen volunteers who were nondiabetic and vitamin D deficient and had BMI>25 kg/m2
were randomized (1:1) in a double-blind manner to a hypocaloric diet1 either oral cholecalciferol at
25,000 IU/wk or placebo for 3 months. Hyperinsulinemic-euglycemic clamp to measure insulin sensitivity
was performed at baseline and after intervention.
Results: Body weight in both groups decreased significantly (27.5% in the vitamin D group and 210% in the
placebo group; P< 0.05 for both), with no between-group differences. Serum 25-hydroxyvitamin D levels in the
vitamin D group increased considerably (from 36.7613.2 nmol/L to 74.8618.7 nmol/L; P<0.001). Insulin sen-
sitivity in the vitamin D group improved (from 4.662.0 to 6.963.3mgkg21min21; P< 0.001), whereas no
changes were observed in the placebo group (from 4.961.1 to 5.160.3mgkg21min21; P50.84).
Conclusions: Cholecalciferol supplementation, combined with a weight loss program, significantly
improves insulin sensitivity in healthy subjects with obesity and might represent a personalized approach
for insulin-resistant subjects with obesity.
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Introduction
Serum 25-hydroxyvitamin D (25[OH]D) concentration has been
reported to be inversely associated with impaired glucose regulation,
insulin resistance, b-cell dysfunction, and risk of metabolic syn-
drome (1,2). Although vitamin D insufficiency, defined as 25(OH)D
levels under 75 nmol/L, is common in subjects with obesity (3),
there is still controversy as to the mechanisms underlying vitamin D
deficiency in obesity. Enhanced adipose tissue uptake (4), altered
vitamin D metabolism in adipose tissue (5), sunlight underexposure,
and low consumption of dairy products have all been postulated as
possible causes. Moreover, it is still unclear whether the concurrence
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of vitamin D deficiency and insulin resistance in obesity is a causal-
ity or merely an independent finding.
Several cross-sectional clinical studies have associated low vitamin
D status with insulin resistance in adults (6) and children (7). Higher
basal levels of 25(OH)D have been found to predict better b-cell
function and lower glycemia in subjects at risk for type 2 diabetes
mellitus (T2DM) (8). Vitamin D may have favorable effects on insu-
lin sensitivity through a series of mechanisms: it increases transcrip-
tional activation and expression of the insulin receptor gene, facili-
tating both basal and insulin-stimulated glucose oxidation and thus
improving insulin sensitivity (9); enhances insulin action and signal
transduction by regulating extracellular calcium (10); and modulates
cytokine-mediated b-cell apoptosis, an important factor in the devel-
opment and progression of T2DM (11).
In a previous study (12), we reported a direct correlation bet-
ween 25(OH)D concentration and insulin sensitivity, evaluated by
hyperinsulinemic-euglycemic clamp, suggesting that vitamin D defi-
ciency could worsen obesity-related insulin resistance. Since then, fur-
ther studies on the effects of vitamin D supplementation on insulin
resistance have produced inconsistent data, with results from trials
showing either no effect (13) or improvements in insulin action (14) in
a wide range of patient populations. The inconsistency of the findings
is most probably due to differences in the methods used to assess insu-
lin resistance, as indirect indexes of insulin resistance derived from
fasting insulin and glucose mostly reflect hepatic insulin sensitivity,
whereas post-oral glucose tolerance tests (OGTTs) do not account for
all the variables influencing the results, including insulin secretion.
Our aim was therefore to evaluate whether vitamin D supplementation
could ameliorate insulin sensitivity in patients at a high risk for diabe-
tes; we designed a randomized, double-blind, placebo-controlled trial in
which subjects with obesity were supplemented with vitamin D or pla-
cebo on top of a hypocaloric diet to clarify the relationship between
hypovitaminosis D and glucose metabolism, with a particular focus on
insulin resistance, as evaluated by hyperinsulinemic-euglycemic clamp.
Methods
Study protocol
This was a double-blind, randomized, placebo-controlled trial (Clini-
calTrials.gov registration: NCT02020694). The primary outcome
measure was a change from baseline in insulin sensitivity after an
intervention of 3 months.
Secondary outcomes included a change from baseline in glucose toler-
ance and insulin secretion and/or a change from baseline in body com-
position, anthropometric parameters, and phosphocalcic metabolism.
The study protocol was approved by the Ethics Committee of the
Catholic University of the Sacred Heart. All subjects provided writ-
ten informed consent.
Subjects
Participants were recruited from patients attending the outpatient
clinic of the Center for Endocrine and Metabolic Diseases of our hos-
pital, for follow-up of thyroid nodules or overweight or obesity. Male
and female subjects aged 18 to 70 years with BMI 30 kg/m2 and
vitamin D deficiency (serum 25[OH]D< 75 nmol/L), who wished to
be included in a weight loss program were enrolled. The exclusion
criteria are discussed in the Supporting Information Methods.
Intervention
Subjects were blindly randomized (1:1), in a parallel manner, to a stand-
ardized hypocaloric diet1 either oral cholecalciferol at 25,000 IU/wk
or placebo once a week for 3 months. Cholecalciferol was provided
by Abiogen (Dibase cod.A11CC05, 25,000 IU/2.5mL oral solution),
whereas the placebo was manufactured by our hospital pharmacy and
was similar to the study medication in color, smell, and taste. The study
medications were dispensed in identical boxes, sequentially numbered
as per the random allocation list (by the pharmacist who was not
involved in data collection or analysis and who kept the list linking the
randomization code to the participants’ identity and to the delivered
box number). Randomization was carried out in blocks of six by gender
and month of recruitment to ensure gender balance and minimize sea-
sonal changes in vitamin D levels. The principal investigator, the co-
investigators, and the health care providers had no access to these code
breaks and were all blinded to treatment allocation. Compliance to
treatment was assessed by interview and inspection of vitamin D/pla-
cebo bottles supplied to participants and returned at each visit.
In addition, all subjects received dietary counseling from the same
nutritionist, who calculated dietary energy composition by subtracting
500 kcal from the usual individual energy intake, evaluated using the
diet history method and a 3-day recall questionnaire. Diet compliance
was evaluated through changes in anthropometric parameters via food
frequency questionnaires during a monthly nutritional visit.
Assessments
Data on demographics, coexisting illnesses, family history of diabe-
tes, and medications used were collected at the first visit. Anthropo-
metric values (body weight, height, and waist and hip circumfer-
ences), a hormonal assessment (parathyroid hormone, 25[OH]D,
thyroid function), measurement of electrolytes (calcium, phospho-
rus), a serum lipid profile (triglycerides, total cholesterol, high-
density lipoprotein and low-density lipoprotein cholesterol), and a
comprehensive metabolic assessment (OGTT, hyperinsulinemic-
euglycemic clamp) were performed at baseline and after 3 months
of intervention. A detailed description of metabolic assessments has
been added in the Supporting Information Methods.
Body composition
Whole body fat mass, whole body lean mass, and trunk fat mass
were assessed by dual x-ray absorptiometry (Delphi-W densitometer;
Hologic, Marlborough, Massachusetts) at the beginning and at the
end of the intervention.
Statistical analyses
From previous data on a similar cohort of patients with obesity stud-
ied at our Center (13) showing a difference in the mean glucose
infusion rate between the upper and the lower part of serum
25(OH)D (25[OH]D 75 and 50 respectively) of 2.06
1.5mgkg21min21, we determined that a sample size of 18 subjects
for each arm was necessary to detect a difference of 1m/kg per
minute in insulin-mediated glucose uptake on the basis of a type I
error of 0.05 and a type II error of 0.20 (power of 80%).
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Statistical analyses were performed with SPSS (version 20; SPSS,
Chicago, Illinois), and statistical significance was set at P<
0.05.Normality was assessed by using the Shapiro-Wilk test. Results
are reported as mean6 SD for normally distributed data sets or
median for nonnormally distributed variables. Differences in base-
line and follow-up characteristics between the two groups were
tested by using independent t tests for normally distributed continu-
ous variables, Mann-Whitney U tests for skewed variables, and
Pearson’s v2 tests for categorical variables.
Results
Of a total of 45 subjects screened from October 2013 to March 2014,
only 42 were considered eligible for the study. During the first visit,
two subjects were excluded because of high serum levels of vitamin D
and another was excluded because of desire to attempt pregnancy. Six
subjects were diagnosed with diabetes after the baseline OGTT and
were excluded from the study before randomization. The remaining
36 subjects were randomly assigned to either the vitamin D group or
the placebo group. A total of 18 subjects (9 participants for both pla-
cebo and vitamin D group) were included in the analysis. At follow-
up, three participants refused to sign the informed consent, while an
additional eight subjects were lost because of lack of compliance in
attending visits or taking medication, and other seven subjects were
excluded because of noncompliance with the dietary regimen. A flow-
chart (Supporting Information Figure S1) shows the study progression.
More females than males were included. Baseline characteristics
were comparable for both groups (Table 1). In particular, serum lev-
els of vitamin D were similar for both groups (vitamin D:
36.76 13.2 nmol/L, placebo: 34.76 21.2 nmol/L; P5 0.80) as was
insulin sensitivity, expressed as milligrams of glucose consumed per
minute per kilogram of body weight (glucose uptake) during
hyperinsulinemic-euglycemic clamp (vitamin D: 4.66 2.1, placebo:
4.96 1.1mgkg-1min-1 mgkg21min21; P5 0.75).
After 3 months of intervention with hypocaloric diet1 cholecalci-
ferol or placebo, body weight decreased significantly in both groups
(vitamin D: 27.5%, placebo: 210% reduction in body weight;
P5 0.0007 and P5 0.001); while no other between-group differen-
ces were observed (P5 0.68) (Figure 1A).
Plasma 25(OH)D levels increased from 36.76 13.2 to
74.86 18.7 nmol/L in the vitamin D group (P< 0.001) and from
34.76 21.1 to 41.76 7.7 nmol/L in the placebo group (P5 0.41)
(Figure 1B).
Total trunk fat mass, evaluated by dual x-ray absorptiometry,
decreased significantly only in the vitamin D group after treatment
(vitamin D group decreased from 21.16 7.9 to 17.96 7.8 kg,
P5 0.003; placebo group from 23.96 1.1 to 21.56 5.9 kg, P5 0.32),
as reported in Table 2. After 3 months of treatment, a substantial
improvement in insulin sensitivity was observed in the vitamin D
group (from 4.66 2.1 to 6.96 3.3mgkg21min21; P< 0.001),
TABLE 1 Clinical and biochemical characteristics of all subjects at baseline
Placebo group
(n5 9)
Vitamin D group
(n5 9) P
Age (y) 35.36 11.0 45.56 11.1 0.06
Gender (F/M) 6/3 8/1
Body weight (kg) 1116 12.2 1006 15.8 0.22
BMI (kg/m2) 38.76 9.75 36.66 5.14 0.50
WHR 0.946 0.03 0.866 0.08 0.13
25(OH)D (nmol/L) 34.76 21.1 36.76 13.2 0.80
Serum calcium (mmol/L) 2.326 0.09 2.316 0.09 0.90
PTH (ng/L) 46.56 1.41 47.86 19.5 0.90
Fasting glucose (mmol/L) 4.786 0.22 5.086 0.55 0.18
Fasting insulin (mUI/mL) 16.86 1.69 13.76 8.59 0.49
Total cholesterol (mmol/L) 4.576 0.66 5.126 0.49 0.22
HDL cholesterol (mmol/L) 1.216 0.27 1.476 0.42 0.22
LDL cholesterol (mmol/L) 2.696 0.22 3.166 0.43 0.22
Triglycerides (mmol/L) 1.436 0.36 1.196 0.60 0.55
AUC glycemia 00-1200(mmol/Lmin104) 85.96 7.70 82.56 19.6 0.62
AUC insulin 00-1200 (mU/mLmin106) 12.36 8.77 9.776 7.90 0.52
Glucose uptake (mgkg21min21) 4.936 1.13 4.626 2.08 0.75
Total fat (%) 38.86 7.42 39.76 7.06 0.81
Trunk lean mass (kg) 32.36 1.04 28.36 5.23 0.20
Trunk fat mass (kg) 23.96 1.10 21.16 7.99 0.46
Data are expressed as mean6SD. P value is for interaction between the two groups.
25(OH)D, 25-hydroxyvitamin D; AUC, area under the curve; F, female; HDL: high-density lipoprotein; LDL: low-density lipoprotein; M, male; PTH, parathyroid hormone;
WHR, waist-hip ratio.
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whereas the change from baseline in glucose uptake during the clamp
procedure was not significant in the placebo group (from 4.96 1.0 to
5.16 0.3mgkg21min21; P5 0.84) (Figure 2). Seventy-five percent
of subjects in the vitamin D group achieved a 20% improvement in
insulin sensitivity, versus 33.3% in the placebo group. Nevertheless,
the improvement in insulin sensitivity achieved in the supplemented
group was not significant compared with the placebo group (P for
interaction5 0.16).
Changes from baseline in glucose and insulin areas under the curve
were nonsignificant and plasma glucose and insulin levels did not
differ at any OGTT time point (Figure 3).
Indirect indexes of b-cell function (i.e., homeostatic model
assessment 2 B, insulinogenic index, disposition index)
remained consistent in both groups. A clinically irrelevant but
statistically significant increment in serum calcium levels was
observed in patients treated with vitamin D (from 2.316 0.09
to 2.396 0.08 mmol/L; P5 0.01), while parathyroid hormone
levels and lipid profiles remained unchanged in both groups
(Table 2).
We noticed that only 60% of subjects in the vitamin D group
reached the target serum 25(OH)D concentration of 75 nmol/L
after treatment. To confirm the relationship between the improve-
ment in insulin sensitivity and vitamin D supplementation, we
performed a further subanalysis on the group treated with Vita-
min D between subjects who reached a 25(OH)D concentration
of 75 nmol/L and those who did not. At follow-up, both sub-
groups showed a significant increase in vitamin D levels (Sup-
porting Information Figure S2A), but only subjects with vitamin
D higher than 75 nmol/L reached the cutoff of normal serum
levels of vitamin D.
Although the subclassification limits the power of analysis, which
doesn’t reach statistical significance, both groups showed an inc-
rease in insulin sensitivity following vitamin D supplementation
(25 [OH]D> 75 nmol/L, P5 0.10; 25[OH]D< 75 nmol/L,
P5 0.18). Further, no difference was observed between groups at
follow-up (P5 0.73) (Supporting Information Figure S2B).
Discussion
This randomized controlled trial compared the effects of a hypo-
caloric diet combined with 3 months of vitamin D supplementation
(25,000 IU weekly) or placebo on insulin sensitivity, measured using
a hyperinsulinemic-euglycemic clamp, in 18 adults with both obesity
and vitamin D deficiency. The study revealed that cholecalciferol
supplementation combined with weight loss is associated with a sig-
nificant improvement in insulin sensitivity in vitamin D deficient
Figure 1 (A) Body weight and (B) 25-hydroxyvitamin D (25[OH]D) levels at baseline (black bars) and after 3 months of
treatment (white bars); *P< 0.001.
Figure 2 Insulin sensitivity (glucose uptake) at baseline (black bars) and after 3 months
of treatment (white bars) in the placebo (PLA) and vitamin D (VITD) groups; *P5 0.02.
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subjects with obesity. However, we failed to demonstrate an
unequivocal effect of cholecalciferol supplementation on insulin sen-
sitivity, as the improvements observed in the vitamin D group were
not significant versus placebo.
A systematic meta-analysis found that vitamin D supplementation
had a bland effect on the reduction of fasting glucose and improve-
ment of insulin resistance in T2DM or impaired glucose tolerance,
but no effect on these variables was noted in patients with obesity
TABLE 2 Biochemical parameters, b-cell function (HOMA2-B, insulinogenic index, disposition index), and body composition at
baseline and after 3 months of treatment in both groups
Placebo group (n5 9) Vitamin D group (n5 9)
Baseline Follow-up P Baseline Follow-up P
25(OH)D (nmol/L) 34.76 21.1 41.76 7.7 0.41 36.76 13.2 74.86 18.7 0.001
Serum calcium (mmol/L) 2.326 0.09 2.326 0.10 0.85 2.316 0.09 2.396 0.08 0.01
PTH (ng/L) 46.56 1.41 40.96 13.6 0.44 47.86 19.5 47.66 20.1 0.97
HOMA2-B 2996 107 2876 105 0.29 1826 84.2 1906 107 0.67
Insulinogenic index 1.306 0.36 1.076 0.33 0.51 2.996 5.40 1.076 0.62 0.32
Disposition index 3.386 0.56 3.896 0.04 0.51 4.896 56.0 4.916 5.84 0.65
Total trunk mass (kg) 56.96 9.50 57.26 10.4 0.35 50.06 11.3 37.46 20.5 0.05
Trunk fat mass (kg) 23.96 11.0 21.56 5.88 0.32 21.16 7.98 17.96 78.3 0.003
Data are expressed as mean6SD. P value is for interaction between baseline and follow-up in each group.
25(OH)D, 25-hydroxyvitamin D; HOMA2-B, homeostatic model assessment 2 B; PTH, parathyroid hormone.
Figure 3 Areas under the curve (AUC) for (A) glycemia and, (B) insulin and (C) glucose and (D) insulin curves during
oral glucose tolerance tests at baseline and after 3 months of treatment in both groups.
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or with normal glucose tolerance (15). In a recently published
randomized controlled trial, Gulseth et al. (16) also observed no
changes in insulin sensitivity or insulin secretion in T2DM patients
after vitamin D3 supplementation. Similarly, Kampmann et al. (17)
found no differences in insulin sensitivity, glycemic control, inflam-
matory parameters, or blood pressure in patients with established
T2DM after 12 weeks of vitamin D supplementation, but they sug-
gested a positive effect on insulin secretion and C-peptide levels in
the vitamin D-treated group.
However, previous reports have suggested that vitamin D can improve
insulin sensitivity both in adolescents and in adults. To date, very few
studies have used the gold standard technique to measure insulin sensi-
tivity (i.e., euglycemic-hyperinsulinemic clamp) in order to assess the
effect of vitamin D supplementation in subjects with overweight or
obesity, and it is therefore difficult to compare these results with data
from other studies using surrogate indexes. In a small group of healthy
male volunteers (n5 18), insulin sensitivity, measured using the
clamp procedure, was similar after either calcitriol or placebo treat-
ment, but these subjects had normal body weight and vitamin D levels
(18). The findings of a recent randomized controlled trial (19) con-
ducted on subjects with overweight or obesity and with no history of
diabetes and vitamin D deficiency contrast with our findings, showing
no difference in insulin sensitivity measured with the use of a
hyperinsulinemic-euglycemic clamp and insulin secretion measured
with the use of an intravenous glucose tolerance test after vitamin D
supplementation compared to placebo, despite a significant increase in
25(OH)D concentrations in the vitamin D group. However, in our
study, subjects showed a reduction in body weight following a hypo-
caloric diet, suggesting that supplementation with vitamin D may have
a greater effect than lifestyle intervention alone in improving insulin
sensitivity in vitamin D deficient subjects with obesity.
In our study, the improvement in insulin resistance following vitamin
D supplementation could be related to the important reduction in trunk
fat mass observed only in the vitamin D group after intervention.
Despite controversial findings on how vitamin D supplementation acts
on body weight or fat mass composition, increases in visceral fat mass
or trunk fat mass were correlated with pathological obesity and fea-
tures of metabolic syndrome in this population (20). A well-designed
randomized controlled trial combining weight loss intervention with
placebo or vitamin D supplementation in 218 women with overweight
or obesity revealed that a 12-month daily supplementation with 2,000
IU cholecalciferol was associated with greater reduction in BMI and
waist circumference only in those subjects whose 25(OH)D levels rose
to 80 nmol/L or higher, suggesting that the beneficial effects of sup-
plementation only kick in at elevated plasma 25(OH)D levels (21).
Other studies have reported that calcium and/or vitamin D supplemen-
tation contributes to a beneficial reduction in visceral adiposity (22)
and have described the mechanism with which such supplements
influence the expression of genes correlated with adipogenesis and
fatty acid oxidation (23). In vitro studies have also shown that the dif-
ferentiation of preadipocytes into mature adipocytes is halted by 1,25-
dihydroxyvitamin D3 (24). Some of these vitamin D effects could be
explained by the expression and activation of different variants of vita-
min D receptors in adipose tissue (25).
An additional factor to consider is the increase in serum calcium
levels reported in subjects treated with vitamin D; indeed, a signifi-
cant inverse correlation between high calcium levels and insulin
resistance has been reported in the literature. This relationship is
probably explained by the interaction between serum calcium levels
and cellular function such as the regulation of glucose uptake in
muscle cells, modulating the insulin receptor and insulin sensitivity
of these cells (26).
We observed a modest, nonsignificant increase in 25(OH)D levels in
the placebo group and no significant improvement in insulin sensi-
tivity despite a clinically relevant 10% weight loss. Serum 25(OH)D
concentrations have been shown to increase following weight loss
(27), although in a large, controlled, retrospective study (28), this
increase did not contribute to improvements in insulin sensitivity
and b-cell function. Furthermore, the improvement in insulin sensi-
tivity in the vitamin D–supplemented group was not significant ver-
sus placebo. Only 60% of subjects in the vitamin D group reached
the target serum 25(OH)D concentration of 75 nmol/L (30 ng/dL),
identified as the optimal value for vitamin D homeostasis in epide-
miological studies (29). However, when we divided the subjects
treated with vitamin D in two subgroups, on the basis of serum
25(OH)D concentration reached after supplementation, we found no
significant difference in insulin sensitivity, glucose tolerance, or
insulin secretion between groups, while both groups showed an
increase in insulin sensitivity following vitamin D supplementation,
suggesting that the effect of vitamin D supplementation on insulin
sensitivity might be independent of the achievement of the cutoff
level of Vitamin D.
Furthermore, we found no improvements in b-cell function due to
vitamin D supplementation, at least as assessed by the disposition
index. Similarly, glucose and insulin areas under the curve during
120-min OGTT did not apparently improve after treatment; this result
is only in apparent contrast with the increase in insulin sensitivity fol-
lowing vitamin D supplementation. An explanation may be that the
sample size is probably too small to catch possible changes in glucose
tolerance; therefore, an improvement in insulin secretion cannot be
excluded. A limited number of interventional studies have examined
the effect of vitamin D supplementation on measures of b-cell func-
tion (30); these studies have, however, yielded inconsistent results. In
a randomized clinical trial, Mitri et al. showed that 16 weeks of chole-
calciferol (2,000 IU daily) supplementation improved b-cell function
in adults at high risk of diabetes (31).
The strengths of our study are the rigorous assessment of both insulin
sensitivity and insulin secretion and the use of gold standard method-
ology for measuring insulin sensitivity; moreover, the study is well
designed, and the participants are well characterized in terms of body
composition and anthropometric measures, despite the small sample
size, which could lead to insufficient power in detecting differences in
study outcomes. Indeed, the main limitation of our study lies in the
number of dropouts due to difficulty in following the hypocaloric diet.
Despite this limitation, the estimated effect size was higher than
anticipated and statistical significance in the primary outcomes
changes was detected, even with the reduced final sample analyzed at
the end of the study.
In conclusion, our data suggest that vitamin D supplementation,
combined with dietary lifestyle intervention, favorably affects insu-
lin sensitivity and body composition, at least in vitamin D deficient
subjects with obesity whose serum levels of vitamin D significantly
increase after treatment. Our data lay the grounds for future, larger
studies aimed at confirming the effect of vitamin D supplementation
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on peripheral and hepatic insulin resistance, with the long-run objec-
tive to investigate personalized strategies for obesity.O
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